{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"RD was defined as the dose that had a dose limiting toxicity (DLT) rate closest to the targeted 20% rate. DLT was an adverse drug reaction and was assessed according to common terminology criteria for adverse events (CTCAE) version (v) 4.03 defined as 1) Grade 4 neutropenia for greater than or equal to (\\>=) 7 days, 2) Grade \\>=3 thrombocytopenia with bleeding, or lasting greater than (\\>) 7 days, 3) Grade \\>=3 febrile neutropenia, 4) Next course of chemotherapy delayed for \\>=7 days, 5) Grade \\>=3 non-hematologic toxicity persisting \\>7 days optimal supportive care, 6) Grade 4 hypertension, confirmed systolic or diastolic blood pressure \\>25 millimeters of mercury (mmHg) above the 95th percentile for age, or an elevated diastolic blood pressure (that is, \\>95th percentile for age) not controlled by a single antihypertensive medication within 14 days of use, 7) Grade 3 proteinuria, 8) Any recurrent Grade 2 non-hematological toxicity requiring \\>=2 interruption and dose reductions.","groups":[{"description":"Participants (of age group 2 to \\<6 years \\[following the completion of run-in period\\] and 6 to \\<18 years) with relapsed or refractory solid malignant tumors received dose of lenvatinib 11 mg/m\\^2, 14 mg/m\\^2 or 17 mg/m\\^2 (administered per BSA, daily dose capped at 24 mg/day) as capsules or suspension (lenvatinib capsules were dissolved in water or apple juice for participants who were unable to swallow capsules and given as suspension), orally, once daily on Days 1 to 28 of each treatment cycle as a single agent until PD, intolerable toxicity, participant noncompliance with safety or efficacy assessments, initiation of another anticancer therapy, voluntary discontinuation by the participant at any time, or study termination by the sponsor, whichever occurred first. Duration of each treatment cycle in Cohort 1=28 days.","id":"OG000","title":"Cohort 1: All Participants"}],"paramType":"NUMBER","populationDescription":"Safety analysis set included all participants who received any study drug and had at least one post-baseline safety evaluation.","reportingStatus":"POSTED","timeFrame":"Cycle 1 (28 days)","title":"Cohort 1: Recommended Dose (RD) of Lenvatinib","type":"PRIMARY","unitOfMeasure":"milligram per square meter (mg/m^2)"}